


Bendazac

Chemical Properties

CAS No. :	20187-55-7
Formula:	C16H14N2O3
Molecular Weight:	282.29
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Bendazac (Bendazolic acid) is an anticataract drug. It may act by preventing protein denaturation.
Targets(IC50)	Others
In vitro	Bendazac (bendazac L-lysine and sodium) inhibits the early stages of protein glycation, as well as the formation of fluorescent advanced glycation products. Bendazac lysine (20 mM) proved to be more effective in inhibiting fluorescence development (67% inhibition) than the corresponding sodium salt (35% inhibition). No significant differences were found with respect to furfural levels; about 40% inhibition was produced with either bendazac lysine or sodium salt. Bendazac clearly inhibits glycation of human lens crystallins, as can be efficiently monitored by following specific changes in lens protein fluorescence[1]

Solubility Information

Solubility	DMSO: 60 mg/mL (212.55 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.08 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.5425 mL	17.7123 mL	35.4246 mL
5 mM	0.7085 mL	3.5425 mL	7.0849 mL
10 mM	0.3542 mL	1.7712 mL	3.5425 mL
50 mM	0.0708 mL	0.3542 mL	0.7085 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Marques C , Ramalho J S , Pereira P , et al. Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac[J]. Documenta Ophthalmologica, 1995, 90(4):395-404.
Lewis B S , Rixon K C , Harding J J . Bendazac prevents cyanate binding to soluble lens proteins and cyanate-induced phase-separation opacities in vitro: a possible mechanism by which bendazac could delay cataract[J]. Experimental Eye Research, 1986, 43(6):0-979.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481